EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase II)Open Access · CC BY-NC-ND 4.0

One‐strength dose escalation of house dust mite depot product for subcutaneous immunotherapy is safe and tolerable

M Jutel iD, C Vogelberg iD, K Duwensee, D Troyke, L Klimek iD

Allergy · 2025

DOI: 10.1111/all.16370 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Allergy, 2025. Verfasst von M Jutel und 4 weiteren Autor:innen. Beteiligte Einrichtung: All-MED Medical Research Institute, Wrocław, Poland. Hauptthemen laut MEDLINE: Desensitization, Immunologic, Pyroglyphidae, Antigens, Dermatophagoides, Allergens. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Allergopharma GmbH & Co. KG.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Allergen immunotherapy (AIT) aims at modulating the immune response by administration of allergen preparations at regular intervals over several years (1). For subcutaneous AIT (SCIT), the treatment is initiated with a dose escalation phase followed by a maintenance dose administration. Over the last decade, there has been a trend towards shortening dose escalation regimens to increase patient adherence. This open‐label, phase II trial aimed to investigate the safety and tolerability of a house dust mites (HDMs) SCIT product when used in a newly designed one‐strength dose escalation scheme.

Method

Patients, aged 12–65, suffering from HDM‐allergic rhinitis/rhinoconjunctivitis ± asthma were included. Patients were randomized to the one‐strength (6 injections from the highest strength 3) or the Standard dose escalation regimen (14 injections from strengths 1 to 3) using the HDMs‐SCIT product. All adverse events were reported. Tolerability was assessed on the Likert scale.

Results

One hundred and forty‐three patients were randomized, 79 adults and 64 adolescents. In total, the one‐strength regimen caused more adverse drug reactions (ADRs) than the Standard regimen ( p = .0457). With both regimens most ADRs were local reactions which occurred more often in the one‐strength group ( p = .0393). But there was no significant difference in the number of patients affected by systemic or serious ADRs between both regimens. No relevant differences occurred between the two age groups and no other risks were observed for adolescents compared to adults.

Conclusion

The safety and tolerability of both regimens can be considered comparable, as most ADRs were local reactions, primarily rated as mild in intensity. Nevertheless, the one‐strength regimen caused more ADRs. Reducing the number of injections from 14 to 6 while using only one strength offers the potential to improve patient adherence which further might increase clinical efficacy. Future trials could confirm this hypothesis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Desensitization, ImmunologicPyroglyphidaeAntigens, DermatophagoidesAllergensHumansAdultMiddle AgedAdolescentMaleFemaleAnimalsAgedInjections, SubcutaneousChildYoung AdultTreatment OutcomeAsthmaRhinitis, Allergic

Stichwörter der Autor:innen

house dust mitesone‐strength dose escalation schemesafetysubcutaneous allergen immunotherapytolerability

Substanzen

Antigens, DermatophagoidesAllergens

Autor:innen und Institutionen

  • All-MED Medical Research Institute, Wrocław, Poland.
  • Department of Clinical Immunology, Faculty of Medicine of Wrocław Medical University, Wrocław, Poland.
  • Department of Pediatrics, Faculty of Medicine and University Hospital Carl Gustav Carus, Technical University Dresden, Dresden, Germany.
  • Allergopharma GmbH & Co. KG, Reinbek, Germany.
  • Center for Rhinology and Allergology, Wiesbaden, Germany.

ORCID-Profile: M Jutel, C Vogelberg, L Klimek

Förderung

  • Allergopharma GmbH & Co. KG

Zitieren

APA

Jutel, M., Vogelberg, C., Duwensee, K., Troyke, D., & Klimek, L. (2025). One‐strength dose escalation of house dust mite depot product for subcutaneous immunotherapy is safe and tolerable. Allergy. https://doi.org/10.1111/all.16370

Vancouver

Jutel M, Vogelberg C, Duwensee K, Troyke D, Klimek L. One‐strength dose escalation of house dust mite depot product for subcutaneous immunotherapy is safe and tolerable. Allergy. 2025. doi:10.1111/all.16370

BibTeX
@article{Jutel2025,
  author = {Jutel, M and Vogelberg, C and Duwensee, K and Troyke, D and Klimek, L},
  title = {One‐strength dose escalation of house dust mite depot product for subcutaneous immunotherapy is safe and tolerable},
  journal = {Allergy},
  year = {2025},
  doi = {10.1111/all.16370}
}
Kostenlos starten →